Breaking Finance News

Why ZELTIQ Aesthetics is up 31 Percent Thursday (ZLTQ)

Shares of ZELTIQ (NASDAQ: ZLTQ) Aesthetics are up 31 percent today after better than expected Q2 earnings. It reported Q2 EPS of $(0.10) versus consensus of $(0.18), beating by $0.08. EPS were up 58 percent year over year. Revenue was reported at $26.30 million versus analyst consensus of $21.58 million. Sales were up 18 percent from the same quarter one year prior.

Other highlights included:

  • Consumable revenue of $13.4 million, up 30 percent year-over-year and 50 percent sequentially
  • Consumable revenue reaches 51 percent of total revenues
  • 136 systems shipped, bringing total system installed base to 1,731

The company develops non-invasive medical technology for the selective reduction of fat.

Mark Foley, President and Chief Executive Officer, said, “I am very pleased with our performance through the first half of 2013. In the second quarter, we expanded our market leadership position due to the continued execution of our sales team combined with growing physician confidence in the clinical performance of our CoolSculpting(R) technology. Our Account Managers continued to expand our market share, placing systems with new customers as well as additional systems with existing customers, while our Product Support Specialists increased utilization by leveraging their new training and marketing tools to achieve strong consumable revenue growth. The results we achieved in the first half of this year reinforce and validate the changes and programs we have put into place thus far. We have increased confidence in the business maintaining this momentum into the second half of the year and we are pleased to be raising our full year revenue guidance.”

[stock-tools exchange="NASDAQ" symbol="ZLTQ" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

New to Breaking Finance News? Read about our format here.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.